CN112569332A - 小柴胡提取物在治疗病毒性肺炎中的应用 - Google Patents
小柴胡提取物在治疗病毒性肺炎中的应用 Download PDFInfo
- Publication number
- CN112569332A CN112569332A CN202011540479.XA CN202011540479A CN112569332A CN 112569332 A CN112569332 A CN 112569332A CN 202011540479 A CN202011540479 A CN 202011540479A CN 112569332 A CN112569332 A CN 112569332A
- Authority
- CN
- China
- Prior art keywords
- extract
- radix
- virus
- bupleurum
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001132254 Bupleurum tenue Species 0.000 title claims abstract description 37
- 239000000284 extract Substances 0.000 title claims abstract description 31
- 206010035737 Pneumonia viral Diseases 0.000 title claims abstract description 22
- 208000009421 viral pneumonia Diseases 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 65
- 241000700605 Viruses Species 0.000 claims abstract description 53
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims abstract description 13
- 241000709687 Coxsackievirus Species 0.000 claims abstract description 12
- 241000711573 Coronaviridae Species 0.000 claims abstract description 11
- 241000598171 Human adenovirus sp. Species 0.000 claims abstract description 9
- 241000430519 Human rhinovirus sp. Species 0.000 claims abstract description 9
- 241000712431 Influenza A virus Species 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 22
- 235000008397 ginger Nutrition 0.000 claims description 22
- 241000202726 Bupleurum Species 0.000 claims description 21
- 241000234314 Zingiber Species 0.000 claims description 20
- 241001522129 Pinellia Species 0.000 claims description 13
- 241000756943 Codonopsis Species 0.000 claims description 11
- 244000126002 Ziziphus vulgaris Species 0.000 claims description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 9
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 9
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims description 8
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 7
- 235000011477 liquorice Nutrition 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 241000007126 Codonopsis pilosula Species 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000006286 aqueous extract Substances 0.000 claims description 5
- 241000207929 Scutellaria Species 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000005325 percolation Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 241000202807 Glycyrrhiza Species 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000012675 alcoholic extract Substances 0.000 claims description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 abstract description 20
- 230000002401 inhibitory effect Effects 0.000 abstract description 17
- 241000700584 Simplexvirus Species 0.000 abstract description 12
- 241000342334 Human metapneumovirus Species 0.000 abstract description 11
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 210000004072 lung Anatomy 0.000 description 56
- 241000699670 Mus sp. Species 0.000 description 50
- 229940079593 drug Drugs 0.000 description 39
- 230000000694 effects Effects 0.000 description 37
- 238000002474 experimental method Methods 0.000 description 32
- 230000005764 inhibitory process Effects 0.000 description 28
- 239000002245 particle Substances 0.000 description 27
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 23
- 229960000329 ribavirin Drugs 0.000 description 23
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 23
- 239000013641 positive control Substances 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 206010037660 Pyrexia Diseases 0.000 description 12
- 239000008187 granular material Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- 230000008673 vomiting Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000000692 Student's t-test Methods 0.000 description 8
- 206010047700 Vomiting Diseases 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 230000003285 pharmacodynamic effect Effects 0.000 description 8
- 230000003449 preventive effect Effects 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 230000002685 pulmonary effect Effects 0.000 description 8
- 238000012353 t test Methods 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 241000709661 Enterovirus Species 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 241001493065 dsRNA viruses Species 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 206010061428 decreased appetite Diseases 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 3
- 206010013789 Dry throat Diseases 0.000 description 3
- 206010013954 Dysphoria Diseases 0.000 description 3
- 240000004534 Scutellaria baicalensis Species 0.000 description 3
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 3
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 3
- 229940015301 baicalein Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008767 xiaochaihu Substances 0.000 description 3
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- GZCXIMGMPAZPPM-UHFFFAOYSA-N 3-methylicosane Chemical compound CCCCCCCCCCCCCCCCCC(C)CC GZCXIMGMPAZPPM-UHFFFAOYSA-N 0.000 description 2
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000510654 Bupleurum chinense Species 0.000 description 2
- 241000213015 Bupleurum scorzonerifolium Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- QJYYMNOTJXIOBP-UHFFFAOYSA-N Ethyl tridecanoate Chemical compound CCCCCCCCCCCCC(=O)OCC QJYYMNOTJXIOBP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 241000711504 Paramyxoviridae Species 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 241001522232 Pinellia ternata Species 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 2
- 229960003321 baicalin Drugs 0.000 description 2
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- MGWAVDBGNNKXQV-UHFFFAOYSA-N diisobutyl phthalate Chemical compound CC(C)COC(=O)C1=CC=CC=C1C(=O)OCC(C)C MGWAVDBGNNKXQV-UHFFFAOYSA-N 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229940067592 ethyl palmitate Drugs 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 235000002780 gingerol Nutrition 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- WTWWTKPAEZQYPW-UHFFFAOYSA-N heptadecan-9-ol Chemical compound CCCCCCCCC(O)CCCCCCCC WTWWTKPAEZQYPW-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- CAWHJQAVHZEVTJ-UHFFFAOYSA-N methylpyrazine Chemical compound CC1=CN=CC=N1 CAWHJQAVHZEVTJ-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- KYWIYKKSMDLRDC-UHFFFAOYSA-N undecan-2-one Chemical compound CCCCCCCCCC(C)=O KYWIYKKSMDLRDC-UHFFFAOYSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000004916 vomit Anatomy 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IWTMSCUHCJHPPR-ACCUITESSA-N (E)-hexadec-2-enedioic acid Chemical compound OC(=O)CCCCCCCCCCCC\C=C\C(O)=O IWTMSCUHCJHPPR-ACCUITESSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- DVWSXZIHSUZZKJ-UHFFFAOYSA-N 18:3n-3 Natural products CCC=CCC=CCC=CCCCCCCCC(=O)OC DVWSXZIHSUZZKJ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QXDWRXCXHXYLNC-UHFFFAOYSA-N 4-phenylheptan-4-ylbenzene Chemical class C=1C=CC=CC=1C(CCC)(CCC)C1=CC=CC=C1 QXDWRXCXHXYLNC-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000605445 Anemarrhena asphodeloides Species 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010025102 Lung infiltration Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241000351643 Metapneumovirus Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- LNOHXHDWGCMVCO-UHFFFAOYSA-N Wogonoside Natural products C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1OC1OC(C(O)=O)C(O)C(O)C1O LNOHXHDWGCMVCO-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 241001247821 Ziziphus Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 229940095076 benzaldehyde Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- MCFZBCCYOPSZLG-UHFFFAOYSA-N cyclopent-4-ene-1,3-dione Chemical compound O=C1CC(=O)C=C1 MCFZBCCYOPSZLG-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
- 229960001826 dimethylphthalate Drugs 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- -1 glycyrrhiza polysaccharides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- DVWSXZIHSUZZKJ-YSTUJMKBSA-N methyl linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OC DVWSXZIHSUZZKJ-YSTUJMKBSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- CUYZUESBPHQWRI-UHFFFAOYSA-N n-(5-methyl-1,2-oxazol-3-yl)acetamide Chemical compound CC(=O)NC=1C=C(C)ON=1 CUYZUESBPHQWRI-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- LNOHXHDWGCMVCO-NTKSAMNMSA-N wogonin 7-O-beta-D-glucuronide Chemical compound C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LNOHXHDWGCMVCO-NTKSAMNMSA-N 0.000 description 1
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
本发明公开了小柴胡提取物在治疗病毒性肺炎中的应用,涉及中药技术领域。本发明公开小柴胡提取物在制备用于治疗病毒性肺炎的药物中的应用。本发明提供的小柴胡提取物对病毒具有较强的抑制作用,且具有更低的使用量,可用于治疗由甲型流感病毒、人鼻病毒、人腺病毒、普通冠状病毒、柯萨奇病毒或副流感病毒引起的肺炎,对单纯疱疹病毒和人偏肺病毒引起的病毒性肺炎无效。本发明为病毒性肺炎的治疗提供了一种新的策略。
Description
技术领域
本发明涉及中药技术领域,具体而言,涉及小柴胡提取物在治疗病毒性肺炎中的应用。
背景技术
小柴胡颗粒,处方来源于《国家食品药品监督管理局标准(试行)》,由柴胡、姜半夏、黄芩、党参、甘草、生姜、大枣共七味中药材组成,具有解表散热,疏肝和胃的功效,用于外感病,邪犯少阳证,症见寒热往来、胸胁苦满、食欲不振、心烦喜呕、口苦咽干。
少阳证,《伤寒论》六经病之一。是指以口苦,咽干,目眩,往来寒热,胸胁苦满,默默不欲饮食,心烦喜呕,脉弦为主症的病变。属于病位既不在表,又未入里的半表半里证,临床上常兼太阳表证或阳明里证。治疗应以和解为原则,小柴胡汤为其代表方。小柴胡汤主治的这种“寒热往来”,既无可汗之表证,又无可下之里证;既无附子干姜可温之寒,也无石膏知母可清之热。“寒热往来”常“如疟状”,但“如疟状”却并非都是本方所主治。如桂枝麻黄各半汤也主“如疟状”,但确是“发热恶寒,热多寒少,其人不呕”;柴胡桂枝干姜汤也治疟,但却为“寒多微有热、或但寒不热”。
小柴胡汤源自汉代医家张仲景的《伤寒杂病论》,主治“少阳病”,少阳病位在半表半里之间,典型表现为“口苦、咽干、目眩、往来寒热、胸胁苦满、默默不欲饮食,心烦喜呕”。在既往的研究报道中,小柴胡汤的主治症状以发热最为多见,尤其是感染性发热,此外对免疫系统发热及不明诱因发热等亦有疗效。
病毒性肺炎是由上呼吸道病毒感染、向下蔓延所致的肺部炎症。本病一年四季均可发生,但大多见于冬春季节,可暴发或散发流行。临床主要表现为发热、头痛、全身酸痛、干咳及肺浸润等。病毒性肺炎的发生与病毒的毒力、感染途径以及宿主的年龄、免疫功能状态等有关。急性呼吸道感染中,病毒感染占90%,其中以流行性感冒病毒为常见,其他为副流感病毒、巨细胞病毒、腺病毒、鼻病毒、冠状病毒和某些肠道病毒,如柯萨奇、埃可病毒等,以及单纯疱疹、风疹、麻疹、人偏肺病毒等病毒。
我国将病毒性肺炎列为常见难治急危重疾病。病毒性肺炎目前尚无特效抗病毒药物,获得公认的抗病毒药物如利巴韦林、阿昔洛韦、更昔洛韦等,但因疗效欠佳、副作用较大、价格昂贵等诸多因素而使用受限。相反,传统中医药对抑制炎症风暴,调节机体免疫等方面具有巨大的优势,因此开发安全有效的抗病毒性肺炎中成药具有重大的意义。
发明内容
本发明的目的在于提供中药组合物在治疗病毒性肺炎中的应用。本发明提供的小柴胡提取物对病毒具有较强的抑制作用,且具有更低的使用量,可用于治疗由甲型流感病毒、人鼻病毒、人腺病毒、普通冠状病毒、柯萨奇病毒或副流感病毒引起的病毒性肺炎,但对由单纯疱疹病毒和人偏肺病毒引起的病毒性肺炎无效。本发明为病毒性肺炎的治疗提供了一种新的策略。
本发明是这样实现的:
小柴胡提取物在制备用于治疗病毒性肺炎的药物中的应用,所述小柴胡提取物由按重量份计的如下组分提取得到:柴胡240份,姜半夏90份、黄芩90份、党参90份、甘草90份、生姜90份以及大枣90份;
所述病毒性肺炎由如下病毒中的任意一种引起:甲型流感病毒、人鼻病毒、人腺病毒、普通冠状病毒、柯萨奇病毒和副流感病毒。
柴胡:伞形科植物柴胡或狭叶柴胡的干燥根。辛、苦,微寒。归肝、胆、肺经。具有疏散退热,疏肝解郁,升举阳气。临床上用于感冒发热,寒热往来,胸胁胀痛,月经不调,子宫脱垂,脱肛。实验证实柴胡具有解热、镇静镇痛、抗炎、抗病原体等作用。柴胡根含挥发油、柴胡醇、油酸、亚麻酸、棕榈酸、硬脂酸、葡萄糖及皂苷等。
姜半夏:半夏是天南星科植物半夏的干燥块茎,姜半夏是半夏的炮制加工品。辛,温。归脾、胃、肺经。具有温中化痰,降逆止呕的功效。临床上用于痰饮呕吐,胃脘痞满。实验证实姜半夏具有镇咳作用、抑制腺体分泌的作用、镇吐和催吐作用。其主要成分为挥发油如3-乙酰氨基-5-甲基异唑,丁基乙烯基醚,3-甲基二十烷,十六碳烯二酸,还有2-氯丙烯酸甲酯,茴香脑,苯甲醛,1,5-戊二醇,2-甲基吡嗪,柠檬醛,1-辛烯,β榄香烯,2-十一烷酮,9-十七烷醇,棕榈酸乙酯。还含左旋麻黄碱,胆碱,β-谷甾醇,胡萝卜甙,原儿茶醛,姜辣烯酮,黄芩甙,黄芩甙元,姜辣醇。另含多糖,直链淀粉,和胰蛋白酶抑制剂。
黄芩:唇形科植物黄芩的干燥根。苦,寒。归肺、胆、脾、大肠、小肠经。具有清热燥湿,泻火解毒,止血,安胎的作用。临床上用于湿温、暑湿,胸闷呕恶,湿热痞满,泻痢,黄疸,肺热咳嗽,高热烦渴,血热吐衄,痈肿疮毒,胎动不安。实验证实抗炎抗变态反应、抗微生物作用、解热作用、降压、利尿等作用。黄芩含黄芩苷元、黄芩苷、汉黄芩素、汉黄芩苷和黄芩新素,还含苯甲酸和β-谷甾醇等。
党参:本品为桔梗科植物党参、素花党参、川党参的干燥根。甘,平。归脾、肺经。健脾益肺,养血生津。临床上用于脾肺气虚,食少倦怠,咳嗽虚喘,气血不足,面色萎黄,心悸气短,津伤口渴,内热消渴。实验证实具有促进凝血、提高血糖、舒张血管、增强心肌收缩力。党参含皂苷、微量生物碱、蔗糖、葡萄糖、菊糖、淀粉、粘液及树脂等。
甘草:豆科植物甘草、胀果甘草或光果甘草的干燥根和根茎。甘平,归心、肺、脾胃经。具有补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。临床上用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多、脘腹、四肢挛急疼痛痈肿疮毒,缓解药物毒性、烈性。实验证实甘草具有抗炎抑菌、去痰止咳等功效。甘草的化学成分主要含有三萜类、黄酮类和甘草多糖类。
大枣:鼠李科植物枣的干燥成熟果实,甘,温。归脾、胃、心经。具有补中益气,养血安神的功效。临床上用于脾虚食少,乏力便溏,妇人脏躁。实验证实大枣对神经有抑制作用,对肝脏有保护作用,可以增强肌力作用,抗癌抗突变抗脂质过氧化作用等。大枣挥发油成分主要有邻苯二甲酸二甲酯、十三烷酸乙酯、邻苯二甲酸二异丁酯、3-羟基-2-丁酮、糠醇、2-环戊烯-1,4-二酮、十六酸乙酯和亚麻酸甲酯酸等。
生姜:姜科植物的新鲜根茎,辛,微温。归肺、脾、胃经。本品具有解表散寒,温中止呕,化痰止咳,解鱼蟹毒的功效。用于风寒感冒,胃寒呕吐,寒痰咳嗽,鱼蟹中毒。实验证实生姜对神经有抑制作用,对肝脏有保护作用,增强肌力作用,抗癌抗突变抗脂质过氧化作用等。现代研究表明生姜的主要成分是挥发油类、姜辣素类和二苯基庚烷类。
本发明的研究显示,采用上述配方提取的小柴胡提取物具有明显的抗病毒作用,其对病毒的抑制作用明显,具有更低的使用量,可用于治疗因甲型流感病毒、腺病毒、普通冠状病毒、柯萨奇病毒或副流感病毒引起的肺炎,而对单纯疱疹病毒和人偏肺病毒引起的病毒性肺炎无效。本发明为病毒性肺炎的治疗提供了一种新的策略。
在可选的实施方式中,所述药物的规格为5g/袋,所述药物按如下方式口服给药:一日3次,一次5g。
在可选的实施方式中,所述小柴胡提取物由柴胡、黄芩、党参、甘草和大枣制得的水提物与由姜半夏和生姜制得的醇提物混合制得。
在可选的实施方式中,所述小柴胡提取物由柴胡、黄芩、党参、甘草和大枣制得的水提物与由姜半夏和生姜制得的醇提物混合后再进行浓缩和干燥后制得。
在可选的实施方式中,所述水提物通过如下方法制得:
将柴胡、黄芩、党参、甘草和大枣与水混合进行煎煮,固液分离后,取液体组分即为所述水提物。
在可选的实施方式中,水的用量为柴胡、黄芩、党参、甘草和大枣总质量的10-12倍。
在可选的实施方式中,煎煮次数为2-3次;每次煎煮时间为1-1.5h。
在可选的实施方式中,所述醇提物通过如下方法制得:
采用醇溶剂对姜半夏和生姜进行浸渍后,再进行渗漉,收集漉液,即为所述醇提物。
在可选的实施方式中,所述醇溶剂为乙醇。
在可选的实施方式中,所述乙醇的浓度为70%-80%。
在可选的实施方式中,进行渗漉时的溶剂流速为1-3ml/min。
在可选的实施方式中,进行浓缩时,在48-52℃条件浓缩至密度1.15~1.20。
在可选的实施方式中,干燥的方式为喷雾干燥。
在可选的实施方式中,本发明所述的小柴胡提取物也可以通过市场购买得到,例如购自北京汉典制药有限公司的小柴胡颗粒(国药准字:Z20043472)。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将对本发明实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
以下结合实施例对本发明的特征和性能作进一步的详细描述。
实施例1
本实施例提供小柴胡颗粒的制备方法,该小柴胡颗粒由按重量份计的如下中药组分制成:柴胡240g,姜半夏90g、黄芩90g、党参90g、甘草90g、生姜90g和大枣90g;
其制备方法包括如下步骤:
步骤1:按照所述重量份准备原料药。
步骤2:取柴胡、黄芩、党参、甘草、大枣五味,加水12倍,煎煮二次,每次1.5小时,合并煎液,滤过,滤液浓缩至适量。
步骤3:姜半夏及生姜用70%的乙醇作溶剂,浸渍24小时后,以每分钟1~3ml的速度缓缓渗漉,收集漉液约900ml,回收乙醇,浓缩至适量。
步骤4:将步骤2及步骤3浓缩液合并,继续浓缩至密度为1.15~1.20(50℃)的清膏,喷雾干燥,获得喷干粉;加粘合剂混合,干法制粒,得颗粒390g即为本实施例提供小柴胡颗粒,每袋装5g,共78袋。
实验例1
小柴胡提取物抗甲型流感病毒性肺炎药效学实验
(1)实验材料:
供试药:小柴胡颗粒(由实施例1提供);阳性对照药(利巴韦林颗粒,湖南千金湘江药业股份有限公司,批号H20044779)。动物:Balb/c小鼠,雌雄各半,13-15g。甲型H1N1流感病毒:中国预防医学科学院病毒学研究所提供。
(2)实验方法:
Balb/c小鼠,随机分6组,每组10只,分别为正常对照组、病毒对照组、供试药高(4.5g/kg)、中(2.25g/kg)、低(1.13g/kg)三个剂量组和阳性对照药利巴韦林颗粒组。除正常对照组外,小鼠用乙醚轻度麻醉,滴鼻感染15LD50甲型H1N1流感病毒。感染后开始给药或生理盐水,每天1次,连续7天,第8天称取小鼠体重,处死解剖取肺称重,逐个计算肺重量指数,并求出肺指数抑制率。肺重量指数值越大,表示肺病变程度越严重。数据处理运用SPSS17.0软件完成,组间比较采用t检验。
(3)实验结果
表1各组药物对病毒感染小鼠肺指数和抑制率的影响
与正常对照组相比,##p<0.01;与病毒模型组相比,**p<0.01,*p<0.05
结果显示,本发明药物对小鼠甲型流感病毒性肺炎具有显著抑制作用,高、中剂量小柴胡给药肺指数抑制率高于利巴韦林阳性对照。结果表明,实施例1的小柴胡颗粒有较好的抗甲型流感病毒作用。
实验例2
小柴胡提取物抗人鼻病毒性肺炎药效学实验
(1)实验材料:
供试药:小柴胡颗粒(由实施例1提供);阳性对照药(利巴韦林颗粒,湖南千金湘江药业股份有限公司,批号H20044779)。动物:Balb/c小鼠,雌雄各半,13-15g。人鼻病毒:中国预防医学科学院病毒学研究所提供。
(2)实验方法:
Balb/c小鼠,随机分6组,每组10只,分别为正常对照组、病毒对照组、供试药高(4.5g/kg)、中(2.25g/kg)、低(1.13g/kg)三个剂量组和阳性对照药利巴韦林颗粒组。除正常对照组外,小鼠用乙醚轻度麻醉,滴鼻感染15LD50人鼻病毒。感染后开始给药或生理盐水,每天1次,连续7天,第8天称取小鼠体重,处死解剖取肺称重,逐个计算肺重量指数,并求出肺指数抑制率。肺重量指数值越大,表示肺病变程度越严重。数据处理运用SPSS17.0软件完成,组间比较采用t检验。
(3)实验结果
表2各组药物对病毒感染小鼠肺指数和抑制率的影响
与正常对照组相比,##p<0.01;与病毒模型组相比,**p<0.01,*p<0.05
结果显示,本发明药物对小鼠人鼻病毒性肺炎具有显著抑制作用,高、中、低剂量小柴胡给药肺指数抑制率高于利巴韦林阳性对照。结果表明,实施例1的小柴胡颗粒具有较好的抗人鼻病毒作用。
实验例3
小柴胡提取物抗人腺病毒性肺炎药效学实验
(1)实验材料:
供试药:小柴胡颗粒(由实施例1提供);阳性对照药(利巴韦林颗粒,湖南千金湘江药业股份有限公司,批号H20044779)。动物:Balb/c小鼠,雌雄各半,13-15g。人腺病毒:中国预防医学科学院病毒学研究所提供。
(2)实验方法:
Balb/c小鼠,随机分6组,每组10只,分别为正常对照组、病毒对照组、供试药高(4.5g/kg)、中(2.25g/kg)、低(1.13g/kg)三个剂量组和阳性对照药利巴韦林颗粒组。除正常对照组外,小鼠用乙醚轻度麻醉,滴鼻感染15LD50腺病毒。感染后开始给药或生理盐水,每天1次,连续7天,第8天称取小鼠体重,处死解剖取肺称重,逐个计算肺重量指数,并求出肺指数抑制率。肺重量指数值越大,表示肺病变程度越严重。数据处理运用SPSS17.0软件完成,组间比较采用t检验。
(3)实验结果
表3各组药物对病毒感染小鼠肺指数和抑制率的影响
与正常对照组相比,##p<0.01;与病毒模型组相比,**p<0.01,*p<0.05
结果显示,本发明药物对小鼠人腺病毒性肺炎具有显著抑制作用,高、中、低剂量小柴胡给药肺指数抑制率高于利巴韦林阳性对照。结果表明,实施例1的小柴胡颗粒具有较好的抗人腺病毒作用。
实验例4
小柴胡提取物抗普通冠状病毒性肺炎药效学实验
(1)实验材料:
供试药:小柴胡颗粒(由实施例1提供);阳性对照药(利巴韦林颗粒,湖南千金湘江药业股份有限公司,批号H20044779)。动物:Balb/c小鼠,雌雄各半,13-15g。普通冠状病毒:中国预防医学科学院病毒学研究所提供。
(2)实验方法:
Balb/c小鼠,随机分6组,每组10只,分别为正常对照组、病毒对照组、供试药高(4.5g/kg)、中(2.25g/kg)、低(1.13g/kg)三个剂量组和阳性对照药利巴韦林颗粒组。除正常对照组外,小鼠用乙醚轻度麻醉,滴鼻感染15LD50普通冠状病毒。感染后开始给药或生理盐水,每天1次,连续7天,第8天称取小鼠体重,处死解剖取肺称重,逐个计算肺重量指数,并求出肺指数抑制率。肺重量指数值越大,表示肺病变程度越严重。数据处理运用SPSS17.0软件完成,组间比较采用t检验。
(3)实验结果
表4各组药物对病毒感染小鼠肺指数和抑制率的影响
与正常对照组相比,##p<0.01;与病毒模型组相比,**p<0.01,*p<0.05
结果显示,本发明药物对小鼠普通冠状病毒性肺炎具有显著抑制作用,高、中、低剂量小柴胡给药肺指数抑制率高于利巴韦林阳性对照。结果表明,实施例1的小柴胡颗粒具有较好的抗普通冠状病毒作用。
实验例5
小柴胡提取物抗柯萨奇病毒性肺炎药效学实验
(1)实验材料:
供试药:小柴胡颗粒;阳性对照药(利巴韦林颗粒,湖南千金湘江药业股份有限公司,批号H20044779)。动物:Balb/c小鼠,雌雄各半,13-15g。柯萨奇病毒:中国预防医学科学院病毒学研究所提供。
(2)实验方法:
Balb/c小鼠,随机分6组,每组10只,分别为正常对照组、病毒对照组、供试药高(4.5g/kg)、中(2.25g/kg)、低(1.13g/kg)三个剂量组和阳性对照药利巴韦林颗粒组。除正常对照组外,小鼠用乙醚轻度麻醉,滴鼻感染15LD50柯萨奇病毒。感染后开始给药或生理盐水,每天1次,连续7天,第8天称取小鼠体重,处死解剖取肺称重,逐个计算肺重量指数,并求出肺指数抑制率。肺重量指数值越大,表示肺病变程度越严重。数据处理运用SPSS17.0软件完成,组间比较采用t检验。
(3)实验结果
表5各组药物对病毒感染小鼠肺指数和抑制率的影响
与正常对照组相比,##p<0.01;与病毒模型组相比,**p<0.01,*p<0.05
结果显示,本发明药物对小鼠柯萨奇病毒性肺炎具有显著抑制作用,高、中剂量小柴胡给药肺指数抑制率高于利巴韦林阳性对照。结果表明,实施例1的小柴胡颗粒具有较好的抗柯萨奇病毒作用。
实验例6
小柴胡提取物抗单纯疱疹病毒性肺炎药效学实验
(1)实验材料:
供试药:小柴胡颗粒(由实施例1提供);阳性对照药(利巴韦林颗粒,湖南千金湘江药业股份有限公司,批号H20044779)。动物:Balb/c小鼠,雌雄各半,13-15g。单纯疱疹病毒:中国预防医学科学院病毒学研究所提供。
(2)实验方法:
Balb/c小鼠,随机分6组,每组10只,分别为正常对照组、病毒对照组、供试药高(4.5g/kg)、中(2.25g/kg)、低(1.25g/kg)三个剂量组和阳性对照药利巴韦林颗粒组。除正常对照组外,小鼠用乙醚轻度麻醉,滴鼻感染15LD50单纯疱疹病毒。感染后开始给药或生理盐水,每天1次,连续7天,第8天称取小鼠体重,处死解剖取肺称重,逐个计算肺重量指数,并求出肺指数抑制率。肺重量指数值越大,表示肺病变程度越严重。数据处理运用SPSS17.0软件完成,组间比较采用t检验。
(3)实验结果
表6各组药物对病毒感染小鼠肺指数和抑制率的影响
与正常对照组相比,##p<0.01;与病毒模型组相比,**p<0.01,*p<0.05
结果显示,本发明药物对小鼠单纯疱疹病毒性肺炎无明显抑制作用。结果表明,实施例1的小柴胡颗粒对单纯疱疹病毒性肺炎无显著抑制作用。
实验例7
小柴胡提取物抗副流感病毒性肺炎药效学实验
(1)实验材料:
供试药:小柴胡颗粒(由实施例1提供);阳性对照药(利巴韦林颗粒,湖南千金湘江药业股份有限公司,批号H20044779)。动物:Balb/c小鼠,雌雄各半,13-15g。副流感病毒:中国预防医学科学院病毒学研究所提供。
(2)实验方法:
Balb/c小鼠,随机分6组,每组10只,分别为正常对照组、病毒对照组、供试药高(4.5g/kg)、中(2.25g/kg)、低(1.13g/kg)三个剂量组和阳性对照药利巴韦林颗粒组。除正常对照组外,小鼠用乙醚轻度麻醉,滴鼻感染15LD50副流感病毒。感染后开始给药或生理盐水,每天1次,连续7天,第8天称取小鼠体重,处死解剖取肺称重,逐个计算肺重量指数,并求出肺指数抑制率。肺重量指数值越大,表示肺病变程度越严重。数据处理运用SPSS17.0软件完成,组间比较采用t检验。
(3)实验结果
表7各组药物对病毒感染小鼠肺指数和抑制率的影响
与正常对照组相比,##p<0.01;与病毒模型组相比,**p<0.01,*p<0.05
结果显示,本发明药物对小鼠副流感病毒性肺炎具有显著抑制作用,高、中、低剂量小柴胡给药肺指数抑制率高于利巴韦林阳性对照。结果表明,实施例1的小柴胡颗粒具有较好的抗副流感病毒作用。
实验例8
小柴胡提取物抗人偏肺病毒性肺炎药效学实验
(1)实验材料:
供试药:小柴胡颗粒(由实施例1提供);阳性对照药(利巴韦林颗粒,湖南千金湘江药业股份有限公司,批号H20044779)。动物:Balb/c小鼠,雌雄各半,13-15g。人偏肺病毒:中国预防医学科学院病毒学研究所提供。
(2)实验方法:
Balb/c小鼠,随机分6组,每组10只,分别为正常对照组、病毒对照组、供试药高(4.5g/kg)、中(2.25g/kg)、低(1.13g/kg)三个剂量组和阳性对照药利巴韦林颗粒组。除正常对照组外,小鼠用乙醚轻度麻醉,滴鼻感染15LD50人偏肺病毒。感染后开始给药或生理盐水,每天1次,连续7天,第8天称取小鼠体重,处死解剖取肺称重,逐个计算肺重量指数,并求出肺指数抑制率。肺重量指数值越大,表示肺病变程度越严重。数据处理运用SPSS17.0软件完成,组间比较采用t检验。
(3)实验结果
表8各组药物对病毒感染小鼠肺指数和抑制率的影响
与正常对照组相比,##p<0.01;与病毒模型组相比,**p<0.01,*p<0.05
结果显示,本发明药物对小鼠人偏肺病毒性肺炎无明显抑制作用。结果表明,实施例1的小柴胡颗粒对人偏肺病毒性肺炎无显著抑制作用。
从上述结果可以看出,本发明实施例提供的小柴胡颗粒对甲型流感病毒、人鼻病毒、人腺病毒、普通冠状病毒、柯萨奇病毒和副流感病毒有抑制作用,但对单纯疱疹病毒和人偏肺病毒无显著抑制作用,可见,本领域技术人员难以预期小柴胡颗粒对病毒的抑制作用。出现上述结果的可能性分析如下:
甲型流感病毒是正粘病毒科的单链RNA病毒,冠状病毒属冠状病毒科单股正链RNA病毒,两者均扩散侵入呼吸道上皮,导致坏死性支气管炎和弥漫性肺泡损伤;人腺病毒是腺病毒科的一种双链DNA病毒,引起呼吸道上皮细胞裂解并影响终末细支气管远端;人鼻病毒是小RNA病毒科鼻病毒属的一种,对呼吸道上皮细胞无破坏作用,但导致上皮屏障破坏,造成血管通透性和粘液分泌增加;人副流感病毒属副黏病毒科单链RNA病毒,通过与呼吸道纤毛上皮结合而引起呼吸系统疾病;柯萨奇病毒属于小核糖核酸病毒科肠道病毒属的单正链RNA病毒,病毒开始在肠道、上呼吸道的内皮细胞和淋巴组织内复制,经血行传播。
人偏肺病毒属副黏病毒科RNA病毒,可感染肺上皮细胞并诱导炎症级联反应;单纯疱疹病毒属疱疹病毒科,是一类具有包膜的DNA病毒,增殖速度快,可引起细胞病变。大部分的病毒主要是通过胞吞和膜融合两种方式将其核酸物质穿过细胞膜屏障,进入细胞。而上述实验中,人偏肺病毒和单纯疱疹病毒主要采用膜融合进入细胞,其余病毒主要以胞吞作用进入细胞,而本发明物其主要的机制可能是抑制病毒与细胞上靶点的结合,阻止其进入细胞。此外,上述结果中响应药物治疗的病毒多在呼吸道上皮细胞感染进入细胞,可能药物抑制病毒进入的靶点也多集中于呼吸道上皮细胞,而对于其它部位的细胞由于缺乏相应的作用靶点导致无明显抑制作用。
以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.小柴胡提取物在制备用于治疗病毒性肺炎的药物中的应用,其特征在于,所述小柴胡提取物由按重量份计的如下组分提取得到:柴胡240份,姜半夏90份、黄芩90份、党参90份、甘草90份、生姜90份以及大枣90份;
所述病毒性肺炎由如下病毒中的任意一种引起:甲型流感病毒、人鼻病毒、人腺病毒、普通冠状病毒、柯萨奇病毒和副流感病毒。
2.根据权利要求1所述的应用,其特征在于,所述药物的规格为5g/袋,所述药物按如下方式口服给药:一日3次,一次5g。
3.根据权利要求1或2所述的应用,其特征在于,所述小柴胡提取物由柴胡、黄芩、党参、甘草和大枣提取的水提物与由姜半夏和生姜提取的醇提物混合制得;
优选的,所述水提物通过如下方法制得:
将柴胡、黄芩、党参、甘草和大枣与水混合进行煎煮,固液分离后,取液体组分即为所述水提物。
4.根据权利要求3所述的应用,其特征在于,水的用量为柴胡、黄芩、党参、甘草和大枣总质量的10-12倍。
5.根据权利要求4所述的应用,其特征在于,煎煮次数为2-3次;每次煎煮时间为1-1.5h。
6.根据权利要求3所述的应用,其特征在于,所述醇提物通过如下方法制得:
采用醇溶剂对姜半夏和生姜进行浸渍后,再进行渗漉,收集漉液,即为所述醇提物。
7.根据权利要求6所述的应用,其特征在于,所述醇溶剂为乙醇;
优选的,所述乙醇的浓度为70%-80%。
8.根据权利要求7所述的应用,其特征在于,进行渗漉时的溶剂流速为1-3ml/min。
9.根据权利要求2所述的应用,其特征在于,进行浓缩时,在48-52℃条件浓缩至密度1.15~1.20。
10.根据权利要求2所述的应用,其特征在于,干燥的方式为喷雾干燥。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011540479.XA CN112569332A (zh) | 2020-12-23 | 2020-12-23 | 小柴胡提取物在治疗病毒性肺炎中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011540479.XA CN112569332A (zh) | 2020-12-23 | 2020-12-23 | 小柴胡提取物在治疗病毒性肺炎中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112569332A true CN112569332A (zh) | 2021-03-30 |
Family
ID=75139102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011540479.XA Pending CN112569332A (zh) | 2020-12-23 | 2020-12-23 | 小柴胡提取物在治疗病毒性肺炎中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112569332A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113082187A (zh) * | 2021-04-09 | 2021-07-09 | 北京红太阳药业有限公司 | 小柴胡提取物与阿奇霉素联合在治疗病毒性肺炎中的应用 |
CN113171437A (zh) * | 2021-05-10 | 2021-07-27 | 北京汉典制药有限公司 | 小柴胡组合物在制备抗冠状病毒的抗病毒制剂中的应用 |
CN115024278A (zh) * | 2022-07-07 | 2022-09-09 | 中国医学科学院医学生物学研究所 | Cv-b1感染啮齿动物手足口病模型的构建方法和用途 |
CN115211402A (zh) * | 2022-07-07 | 2022-10-21 | 中国医学科学院医学生物学研究所 | 一种cv-b3感染的啮齿动物模型的构建方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111358929A (zh) * | 2020-05-14 | 2020-07-03 | 广州白云山光华制药股份有限公司 | 小柴胡颗粒在抑制甲型流感病毒中的新应用 |
CN111467466A (zh) * | 2020-05-13 | 2020-07-31 | 广州白云山光华制药股份有限公司 | 小柴胡颗粒在防治合胞病毒、腺病毒中的新应用 |
-
2020
- 2020-12-23 CN CN202011540479.XA patent/CN112569332A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111467466A (zh) * | 2020-05-13 | 2020-07-31 | 广州白云山光华制药股份有限公司 | 小柴胡颗粒在防治合胞病毒、腺病毒中的新应用 |
CN111358929A (zh) * | 2020-05-14 | 2020-07-03 | 广州白云山光华制药股份有限公司 | 小柴胡颗粒在抑制甲型流感病毒中的新应用 |
Non-Patent Citations (1)
Title |
---|
张金莲: "《中成药学》", 31 August 2018, 中国中医药出版社 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113082187A (zh) * | 2021-04-09 | 2021-07-09 | 北京红太阳药业有限公司 | 小柴胡提取物与阿奇霉素联合在治疗病毒性肺炎中的应用 |
CN113171437A (zh) * | 2021-05-10 | 2021-07-27 | 北京汉典制药有限公司 | 小柴胡组合物在制备抗冠状病毒的抗病毒制剂中的应用 |
CN115024278A (zh) * | 2022-07-07 | 2022-09-09 | 中国医学科学院医学生物学研究所 | Cv-b1感染啮齿动物手足口病模型的构建方法和用途 |
CN115211402A (zh) * | 2022-07-07 | 2022-10-21 | 中国医学科学院医学生物学研究所 | 一种cv-b3感染的啮齿动物模型的构建方法和用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112569332A (zh) | 小柴胡提取物在治疗病毒性肺炎中的应用 | |
CN103463609A (zh) | 治疗上呼吸道感染的中药口服汤剂及其中成药的制备方法 | |
CN102302673B (zh) | 一种预防和治疗糖尿病肾病的中药复方制剂 | |
CN103656122B (zh) | 治疗外感热病的中药及其制备方法 | |
CN106075029B (zh) | 一种防治鸡卫气分证的中药口服液 | |
CN111632116A (zh) | 一种抗病毒性感冒中药制剂的制备方法 | |
CN111298123A (zh) | 抗病毒组合物及其在抗人流感病毒和禽流感病毒中的应用 | |
CN103961614A (zh) | 用于治疗呼吸系统疾病的中药组合物及其制备方法和用途 | |
CN115919963A (zh) | 一种中药组合物在制备治疗新型冠状病毒感染药物中的应用 | |
CN106334171B (zh) | 一种用于修复肝损伤的中药制剂及制备方法 | |
CN104435567A (zh) | 一种含绞股蓝的治疗痛风的中药组合物 | |
CN104306867A (zh) | 一种治疗病毒性心肌炎的中药制剂及制备方法 | |
CN111265554A (zh) | 抗病毒复方组合物在抗hiv病毒、sars病毒和白血病病毒中的应用 | |
CN102755519B (zh) | 葛根葛花抗口腔溃疡颗粒及其制备方法 | |
CN113018344A (zh) | 用于预防治疗流感及上呼吸道感染的中药 | |
CN104524256A (zh) | 一种用于治疗病毒性肺炎的中药 | |
CN110742939A (zh) | 一种中药复方组合物的制备及其治疗上呼吸道感染的应用 | |
CN104208168B (zh) | 一种用于治疗家禽呼吸道感染的复方中药组合物及其制备方法 | |
CN108992580A (zh) | 用于化痰止咳的中药组合物及其制备方法 | |
CN104721767A (zh) | 一种治疗小儿咳嗽的中药组合物及其制备方法 | |
CN113101331B (zh) | 一种百里香药茶及其制备方法和应用 | |
CN103623203B (zh) | 一种咳舒口服制剂的制备方法 | |
CN109820826B (zh) | 一种消炎中药颗粒剂及其制备方法 | |
CN102342995A (zh) | 一种治疗肝硬化肝腹水的药物组合物及其制备方法 | |
CN104644886A (zh) | 一种治疗病毒性心肌炎的中药及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210330 |